Patients at risk of gravidic vascular diseases according to their biological status;Quelles sont les patientes à risque de pathologies vasculaires gravidiques en fonction de leur statut biologique?

Annales de Medecine Interne

Volumn 154, Issue 5-6, 2003, Pages 414-421

  Imbert, Bernard ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; HOMOCYSTEINE; PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; FEMALE; GENE MUTATION; GENETIC DISORDER; HEMOSTASIS; HOMOZYGOTE; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; PREECLAMPSIA; PREGNANCY; RISK FACTOR; SOLUTIO PLACENTAE; THROMBOCYTHEMIA; THROMBOPHILIA; VASCULAR DISEASE;

FEMALE; HUMANS; PLACENTA DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 0346341088     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (82)

1. LOCKWOOD CJ: Heritable coagulopathies in pregnancy. Obstet Gynecol Surv, 1999; 54: 754-65.
2. SAADE GR, MCLINTOCK C: Inherited thrombophilia and stillbirth. Semin Perinatol, 2002; 26: 51-69.
3. GREAVES M, COHEN H, MACHIN SJ, MACKIE I: Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol, 2000; 109: 704-15.
4. ANONYMOUS: Investigation and management of heritable thrombophilia. Br J Haematol, 2001; 114: 512-28.
5. GLUECK CJ, FREIBERG RA, FONTAINE RN, TRACY T, WANG P: Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop, 2001; (386): 19-33.
6. KYRLE PA, MINAR E, HIRSCHL M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med, 2000; 343: 457-62.
7. KHAMASHTA MA: Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus, 1998; 7 (Suppl 2): S162-5.
8. LYNCH A, SILVER R, EMLEN W: Antiphospholipid antibodies in healthy pregnant women. Rheum Dis Clin North Am, 1997; 23: 55-70.
9. GREAVES M: Antiphospholipid syndrome: state of the art with emphasis on laboratory evaluation. Haemostasis, 2000; 30 (Suppl 2): 16-25.
10. TEIXIDO M, FONT J, REVERTER JC, et al.: Anti-beta 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome. Br J Rheumatol, 1997; 36: 113-6.
11. ALFIREVIC Z, ROBERTS D, MARTLEW V: How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol, 2002; 101: 6-14.
12. LOCKSHIN MD: Pregnancy loss in the antiphospholipid syndrome. Thromb Haemost, 1999; 82: 641-8.
13. BALLEM P: Acquired thrombophilia in pregnancy. Semin Thromb Hemost, 1998; 24 (Suppl 1): 41-7.
14. FAUGHT W, GARNER P, JONES G, IVEY B: Changes in protein C and protein S in normal pregnancy. Am J Obstet Gynecol, 1995; 172 (1 Pt 1): 147-50.
15. KJELLBERG U, ANDERSSON NE, ROSEN S, TENGBORN L, HELLGREN M: APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost, 1999; 81: 527-31.
16. KUPFERMINC MJ, ELDOR A, STEINMAN N, et al.: Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med, 1999; 340: 9-13.
17. ALONSO A, SOTO I, URGELLES MF, CORTE JR, RODRIGUEZ M, PINTO CR: Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol, 2002; 187: 1337-42.
18. GRIS JC, QUERE I, MONPEYROUX F, et al.: Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent. The Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost, 1999; 81: 891-9.
19. KUPFERMINC MJ, MANY A, LESSING JB: Thrombophilia polymorphisms and intrauterine growth restriction. N Engl J Med, 2002; 347: 1530-1.
20. KUPFERMINC MJ, MANY A, BAR-AM A, LESSING JB, ASCHER-LANDSBERG J: Mid-trimester severe intrauterine growth restriction is associated with a high prevalence of thrombophilia. BJOG 2002; 109: 1373-6.
21. SARIG G, YOUNIS JS, HOFFMAN R, LANIR N, BLUMENFELD Z, BRENNER B: Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril, 2002; 77: 342-7.
22. PRESTON FE, ROSENDAAL FR, WALKER ID, et al.: Increased fetal loss in women with heritable thrombophilia. Lancet, 1996; 348: 913-6.
23. SANSON BJ, FRIEDERICH PW, SIMIONI P, et al.: The risk of abortion and stillbirth in antithrombin-protein C-, and protein S-deficient women. Thromb Haemost, 1996; 75: 387-8.
24. LINDQVIST PG, SVENSSON PJ, MARSAAL K, GRENNERT L, LUTERKORT M, DAHLBACK B: Activated protein C resistance (facteur V: Q506) and pregnancy. Thromb Haemost, 1999; 81: 532-7.
25. GRANDONE E, MARGAGLIONE M, COLAIZZO M, CAPPUCCI G, VECCHIONE NS, PAVONE G, et al.: Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost, 1997; 5: 822-32.
26. BRENNER B, MANDEL H, LANIR N, YOUNIS J, ROTHBART H: Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol, 1997; 97: 551-4.
27. RIDKER PM, MILETICH JP, BURING JE, et al.: Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med, 1998; 128: 1000-3.
28. FOKA ZJ, LAMBROPOULOS AF, SARAVELOS H, et al.: Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod, 2000; 15: 458-62.
29. YOUNIS JS, BRENNER B, OHEL G, TAL J, LANIR N, BENAMI M: Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol, 2000; 43: 31-5.
30. REZNIKOFF-ETIEVAN MF, CAYOL V, CARBONNE B, ROBERT A, COULET F, MILLIEZ J: Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG, 2001; 108: 1251-4.
31. RAI R, REGAN L, HADLEY E, DAVE M, COHEN H: Second-trimester pregnancy losses associated with activated protein C resistance. Br J Haematol, 1996; 92: 489-90.
32. DIZON-TOWNSON DS, KINNEY S, BRANCH DW, WARD K: The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol, 1997; 34: 217-3.
33. KUTTEH WH, PARK VM, DEITCHER SR: Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril, 1999; 71: 1048-53.
34. MARTINELLI I, TAIOLI E, CETIN I, et al.: Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med, 2000; 343: 1015-8.
35. RAZIEL A, KORNBERG Y, FRIEDLER S, SCHACHTER M, SELA BA, RON-EL R: Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. Am J Reprod Immunol, 2001; 45: 65-71.
36. CARP H, SALOMON O, SEIDMAN D, DARDIK R, ROSENBERG N, INBAL A: Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod, 2002; 17: 1633-7.
37. MANY A, ELAD R, YARON Y, ELDOR A, LESSING JB, KUPFERMINC MJ: Third-trimester unexplained fetal death is associated with inherited thrombophilia. Obstet Gynecol, 2002; 99 (5 Pt 1): 684-7.
38. ROTHBART H, OHEL G, YOUNIS J, LANIR N, BRENNER B: High prevalence of activated protein C resistance due to factor V leiden mutation in cases of intrauterine fetal death. J Matern Fetal Med, 1999; 8: 228-30.
39. WIENER-MEGNAGI Z, BEN-SHLOMO I, GOLDBERG Y, SHALEV E: Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol, 1998; 179 (6 Pt 1): 1565-7.
40. CLARK P, SATTAR N, WALKER ID, GREER IA: The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: Significance of pregnancy associated activated protein C resistance. Thromb Haemost, 2001; 85: 30-5.
41. PICKERING W, HOLMES Z, REGAN, L, COHEN H. Normal prevalence of the G20210A prothrombine mutation in women with recurrent miscarriage. Br J Haematol, 1998; 102: 250.
42. MARTINELLI I, DE STEFANO V, TAIOLI E, PACIARONI K, ROSSI E, MANNUCCI PM: Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost, 2002; 87: 791-5.
43. VOLLSET SE, REFSUM H, TVERDAL A, NYGARD O, NORDREHAUG JE, TELL GS, et al.: Plasma total homocysteine and cardiovascular and non cardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr, 2001; 74: 130-6.
44. BRENNER B, SARIG G, WEINER Z, YOUNIS J, BLUMENFELD Z, LANIR N: Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost, 1999; 82: 6-9.
45. BLUMENFELD Z, BRENNER B: Thrombophilia-associated pregnancy wastage. Fertil Steril, 1999; 72: 765-4.
46. MORRISON ER, MIEDZYBRODZKA ZH, CAMPBELL DM, et al.: Prothrombotic genotypes are not associated with preeclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost, 2002; 87: 779-85.
47. KUPFERMINC MJ, FAIT G, MANY A, GORDON D, ELDOR A, LESSING JB: Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol, 2000; 96: 45-9.
48. LIVINGSTON JC, BARTON JR, PARK V, HADDAD B, PHILLIPS O, SIBAI BM: Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol, 2001; 185: 153-7.
49. GRANDONE E, MARGAGLIONE M, COLAIZZO D, et al.: Lower birth-weight in neonates of mothers carrying factor V G1691A and factor II A(20210) mutations. Haematologica, 2002; 87: 177-81.
50. GRANDONE E, MARGAGLIONE M, COLAIZZO D, CAPPUCCI G, PALADINI D, MARTINELLI P, et al.: Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost, 1997; 77: 1052.
51. REGAN L, RAI R: Thrombophilia and pregnancy loss. J Reprod Immunol, 2002; 55: 163-80.
52. KUPFERMINC MJ, MANY A, LESSING JB: Thrombophilia polymorphisms and intrauterine growth restriction. N Engl J Med, 2002; 347: 1530-1.
53. INFANTE-RIVARD C, RIVARD GE, YOTOV WV, et al.: Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med, 2002; 347: 19-25.
54. RAY JG, LASKIN CA: Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss. A systematic review. Placenta, 1999; 20: 519-29.
55. RAI R, REGAN L. Thrombophilia and adverse pregnancy outcome. Semin Reprod Med, 2000; 18: 369-77.
56. SIMPSON JL, CARSON SA, CHESNEY C, et al.: Lack of association between antiphospholipid antibodies and first-trimester spontaneous abortion: prospective study of pregnancies detected within 21 days of conception. Fertil Steril, 1998; 69: 814-20.
57. RAI RS, CLIFFORD K, COHEN H, REGAN L: High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod, 1995; 10: 3301-4.
58. LYNCH A, BYERS T, EMLEN W, RYNES D, SHETTERLY SM, HAMMAN RF: Association of antibodies to beta-2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Obstet Gynecol, 1999; 93: 193-8.
59. ULCOVA-GALLOVA Z, BOUSE V, KRIZANOVSKA K, BALVIN M, ROKYTA Z, NETRVALOVA L: Beta-2-glycoprotein I is a good indicator of certain adverse pregnancy conditions Int J Fertil Womens Med, 2001; 46: 304-8.
60. GRIS JC, QUERE I, SANMARCO M, et al.: Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss: The Nimes Obstetricians and Haematologists Study - NOHA. Thromb Haemos,t 2000; 84: 228-36.
61. TEFFERI A, HOAGLAND HC: Issues in the diagnosis and management of essential thrombocythemia. Mayo Clin Proc, 1994; 69: 651-5.
62. WRIGHT CA, TEFFERI A: A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol, 2001; 66: 152-9.
63. MACKLON NS, GREER IA: Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J, 1996; 41: 83-6.
64. MARTINELLI I: Risk factors in venous thromboembolism. Thromb Haemost, 2001; 86: 395-403.
65. GRANDONE E, MARGAGLIONE M, COLAIZZO D, et al.: Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol, 1998; 179: 1324-8.
66. MCCOLL MD, RAMSAY JE, TAIT RC, et al.: Risks factors associated venous thromboembolism. Thromb Haemost, 1997; 78: 1183-8.
67. GREER IA: Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in Obstetrics and Gynaecology. Baillieres Clin Obstet Gynaecol, 1997; 11: 403-30.
68. FRIEDERICH PW, SANSON BJ, SIMIONI P, et al.: Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med, 1996; 125: 955-60.
69. CONARD J, HORELLOU MH, VAN DREDEN P, LECOMPTE T, SAMAMA M: Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost, 1990; 63: 319-20.
70. PABINGER I, SCHNEIDER B: Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thromboseund Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol, 1996; 16: 742-8.
71. DE STEFANO V, LEONE G, MASTRANGELO S, et al.: Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost, 1994; 71: 799-800.
72. GERHARDT A, SCHARF RE, BECKMANN MW, et al.: Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med, 2000; 342: 374-80.
73. MARTINELLI I, LEGNANI C, BUCCIARELLI P, GRANDONE E, DE STEFANO V, MANNUCCI PM: Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost, 2001; 86: 800-3.
74. BRILL-EDWARDS P, GINSBERG JS, GENT M, et al.: Safety of withholding heparin in pregnant women with a history of venous thromboembolism. "Recurrence of Clot in This Pregnancy" Study Group. N Engl J Med, 2000; 343: 1439-44.
75. SIMIONI P, TORMENE D, PRANDONI P, et al.: Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood, 2002; 99: 1938-42.
76. BRANCH DW, SILVER RM, BLACKWELL JL, READING JC, SCOTT JR: Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol, 1992; 80: 614-20.
77. LIMA F, KHAMASHTA MA, BUCHANAN NM, KERSLAKE S, HUNT BJ, HUGHES GR: A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol, 1996; 14: 131-6.
78. FORASTIERO R, MARTINUZZO M, ADAMCZUK Y, VARELA ML, POMBO G, CARRERAS LO: The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica, 2001; 86: 735-41.
79. HARRIS EN, PIERANGELI SS, GHARAVI AE: Diagnosis of the antiphospholipid syndrome: a proposal for use of laboratory tests. Lupu,s, 1998; 7 (Suppl 2): S144-8.
80. SILVER RM, PORTER TF, VAN LEEUWEEN I, JENG G, SCOTT JR, BRANCH DW: Anticardiolipin antibodies: clinical consequences of 'low titers'. Obstet Gynecol, 1996; 87: 494-500.
81. KHAMASHTA MA. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus, 1998; 7 (Suppl 2): S162-5.
82. PETRI M: Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am, 1997; 81: 151-77.